Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms

Further Publications

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study

Adv Ther

van der Vorst MJDL, Maximiano Alonso C, Calderón Boyle TA, Schilder JM, Malinowska IA, Ye G, Kroep JR, Mañé Martínez JM, Kuplast J, Perhanidis J, Evans C, Golembesky AK, Tasca G, Kommoss S

doi: 10.1007/s12325-026-03600-9

Leukemia

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification

Haematologica

Berdel AF, Röllig C, Burkhard-Meier C, Tembrink M, Unglaub JM, Sauer T, Crysandt M, Jost E, Jaeger P, Kiefel C, Fransecky L, Braitsch K, Götze K, Wille K, Schäfer-Eckart K, Metzeler K, Hilber S, Ronnacker J, Kemper M, Hölscher N, Wethmar K, Schroeder T, Herold S, Poitz D, Steffen B, Rank A, Hänel M, Middeke JM, Kaufmann M, Burchert A, Schetelig J, Platzbecker U, Thiede C, Stelljes M, Lenz G, Serve H, Baldus C, Bornhäuser M, Müller-Tidow C, Mikesch JH, Frenzel L, Hanoun M, Ruhnke L, Schliemann C

doi: 10.3324/haematol.2026.301102

Leukemia

Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide

Leukemia

Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B

doi: 10.1038/s41375-026-02907-4

Leukemia

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis

Leuk Lymphoma

Huang YH, Liu FT, Wan CL, Wang ZJ, Liu YQ, Cao HY, Huang SM, Tan KW, Ge SS, Wang M, Liu MJ, Wang ZH, Lyu XY, Dai HP, Li Z, Xue SL

doi: 10.1080/10428194.2025.2566317

Leukemia

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Am J Hematol

Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM, Calmet FV, Campbell V, Cetin D, Cimino G, Ciotti G, Corbingi A, De Fazio L, Erol HA, Federico V, Gil C, Gulu YM, Malcorra AB, Mariani S, Mazzone C, Mulè A, Musuraca G, Khan A, Norata M, O'Nions J, Palumbo FE, Papayannidis C, Piccioni AL, Rubio MTO, Sanchez-Tovar J, Serin I, Serrao A, Sevindik OG, Sucato G, Urbano MA, Vetro C, Vives S, Rossi M, Martelli MP, Montesinos P, Othman J, Perrone S

doi: 10.1002/ajh.70142

Leukemia

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience

Br J Haematol

Chan WY, Al-Yousuf H, Lam HPJ, Leong S, Zheng J, Burt R, Wilson AJ, Xu K, Stringaris K, Alimam S, Raj K, Gupta R, Kottaridis P, Tailor A, Burgoyne R, Mansour MR, Khwaja A, Sellar R, Payne EM, O'Nions J

doi: 10.1111/bjh.70676

Leukemia

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

Leukemia

Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, Garcia JS, Rizzieri D, Thirman MJ, Zhang M, Potluri J, Miller C, Dhalla M, Pullarkat V

doi: 10.1038/s41375-025-02730-3

Leukemia

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis

Leuk Lymphoma

Alhajahjeh A, Beke KE, Grimshaw AA, Aguirre LE, Mina A, Podoltsev NA, Mendez L, Stahl M, Zeidan AM, Bewersdorf JP

doi: 10.1080/10428194.2026.2682397

Leukemia

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

Leukemia

Cusan M, Larkin K, Nicolet D, Jurinovic V, Mrózek K, Batcha AMN, Rothenberg-Thurley M, Schneider S, Sauerland C, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Spiekermann K, Greif PA, Blachly JS, Mims AS, Walker CJ, Walker MC, Oakes CC, Orwick S, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Byrd JC, Metzeler KH, Herold T, Eisfeld AK

doi: 10.1038/s41375-025-02644-0

Related content

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification

Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)